Skip to main content

  • Novel Drug Product Creation with new composition-of-Matter IP

    Our technology is a powerful Intellectual Property (IP) engine

Topical therapies are the therapeutic pillar for many diseases, but traditional water- or oil-based formulations have significant limitations that may influence efficacy and safety.

EyeSol® is the worldwide first and only water-free technology for ophthalmic products. It dramatically increases the residual time on the eye from seconds to hours and enables high bioavailability of active pharmaceutical ingredients (API) with excellent tolerability and safety while reducing systemic exposure due to a small drop size (<12 µL).

Thereby EyeSol® unlocks the full potential of APIs by generating novel drug products often even with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.

EyeSol

Our products have the potential to redefine drug therapies. Refer to Products or Pipeline for more insight on how EyeSol® overcomes the limitations in eye care therapies

Novaliq Ophthalmic Pipeline

Dry Eye Disease & General Ophthalmology

EyeSol® Product Indication Preclinics Phase II Phase III NDA Market
Vevizye®
(0.1% ciclosporine in EyeSol®) 		Dry Eye Disease
(anti-inflammatory)
Europe
 		MAA submitted to
EMA
BTQ1902
(timolol 0.5% in EyeSol®) 		Dry Eye Disease
(Elevated Intraocular Pressure)
Global
FDA EoPh2 completed
Phase III U.S. trial initiation
  
BTQ2301
(latanoprost in EyeSol®) 		Dry Eye Disease
(Elevated Intraocular Pressure)
Global
 		 
BTQ2302
(timolol & latanoprost combination) 		Dry Eye Disease
(Elevated Intraocular Pressure)
Global
 		 
BTQ2401
(tacrolimus in in EyeSol®) 		Dry Eye Disease
(Vernal Keratoconjunxtivitis, Severe Refractive Uveitis)
Global
 		 
NQ1910 IQDINE
(iodine molecular in EyeSol®) 		Bacterial / Viral conjunctivitis
Global
Expedited regulatory
path expected
  

Topical Retina Therapies

EyeSol® Product Indication In-vitro In-vivo Tox IND Phase I/II
NQ2010
(Peptide/NCE in EyeSol®) 		Diabetic Retinopathy
(anti-ischemic neuroprotective)
Global
 		   
NQ2020
(Protein in EyeSol®) 		Diabetic Retinopathy
(anti-angiogenic)
Global
 		   
NQ2030
(Small molecule in EyeSol®) 		Diabetic Retinopathy
(anti-oxidant & anti-inflammatory)
Global
 		   
NQ2040
(Peptide in EyeSol®) 		Diabetic Retinopathy
(anti-angiogenic neuroprotective)
Global
 		   
NQ2050
(Small molecule/NCE in EyeSol®) 		Diabetic Retinopathy
(undisclosed)
Global
 		   

Approved CE products: Novatears®, Novatears®+Omega-3